ALNY Alnylam Pharmaceuticals Inc.

71.14
-0.66  -1%
Previous Close 71.8
Open 72
Price To Book 4.9
Market Cap 7,579,026,387
Shares 106,536,778
Volume 331,878
Short Ratio
Av. Daily Volume 1,033,393

NewsSee all news

  1. Alnylam Presents New Data for RNAi Therapeutic Onpattro
  2. Alnylam Presents New ONPATTRO® (patisiran) Results at the 2019 Peripheral Nerve Society Annual Meeting
  3. Alnylam Announces Progress with RNAi Therapeutics Platform, Including Oral Route of Administration and CNS and Ocular Delivery
  4. Here’s What Hedge Funds Think About Alnylam Pharmaceuticals, Inc. (ALNY)
  5. Alnylam Completes Enrollment in Phase III Study of Lumasiran

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Noted September 7, 2017 that Fitusiran program suspended dosing due to fatal thrombotic event. Announced December 15, 2017 that clinical hold has been released. Dosing to resume later December.
Fitusiran
Hemophilia A and B
Rolling NDA completion announced June 5, 2019.
Givosiran
Acute hepatic porphyrias
Phase 3 data 3Q 2019.
Inclisiran - ORION-9
Hypercholesterolemia
Phase 1/2 data due 2019.
ALN-HBV02 (VIR-2218))
Chronic hepatitis B virus (HBV)
Phase 3 data due late-2019.
Lumasiran (ALN-GO1) ILLUMINATE-A
Primary Hyperoxaluria Type 1 (PH1)
FDA Approval announced August 10, 2018.
Patisiran
Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR
Phase 2 trial to be initiated.
ALN-CC5 (cemdisiran)
IgA nephropathy
Phase 3 first read-out expected 2H 2019
Fitusiran (ATLAS)
Hemophilia
Phase 3 trial enrolling - noted December 6, 2018.
ALN-TTRsc02 - HELIOS-A
ATTR amyloidosis
Phase 3 sata due 3Q 2019.
Inclisiran - ORION-10
Cardiovascular disease (ASCVD)
Phase 3 data due 3Q 2019.
Inclisiran - ORION 11
Cardiovascular disease (ASCVD)
Phase 1/2 data due 2019.
ALN-AAT02
alpha-1 anti-trypsin deficiency-associated liver disease
Phase 3 top-line data due mid-2020.
Lumasiran (ALN-GO1) ILLUMINATE-B
Primary Hyperoxaluria Type 1
Phase 3 trial to be initiated mid-2019.
Patisiran APOLLO-B
Wild-type ATTR amyloidosis patients with cardiomyopathy
Phase 3 trial to be initiated mid-2019.
Lumasiran (ALN-GO1) ILLUMINATE-C
Impaired renal function
Phase 1 dosing has commenced - noted May 31, 2019. Initial data due late-2019.
ALN-AGT
Hypertension

Latest News

  1. Alnylam Presents New Data for RNAi Therapeutic Onpattro
  2. Alnylam Presents New ONPATTRO® (patisiran) Results at the 2019 Peripheral Nerve Society Annual Meeting
  3. Alnylam Announces Progress with RNAi Therapeutics Platform, Including Oral Route of Administration and CNS and Ocular Delivery
  4. Here’s What Hedge Funds Think About Alnylam Pharmaceuticals, Inc. (ALNY)
  5. Alnylam Completes Enrollment in Phase III Study of Lumasiran
  6. See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
  7. Alnylam Announces Approval in Japan of ONPATTRO® for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy
  8. Regeneron (REGN) Presents Positive Data on Lymphoma Candidate
  9. Alnylam Completes Enrollment for ILLUMINATE-A Phase 3 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 (PH1)
  10. Why Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Is A Financially Healthy Company
  11. Boston-area biopharm firm has big plans in Philadelphia
  12. Alnylam to Report New Clinical Results for ONPATTRO® (patisiran) at Peripheral Nerve Society (PNS) Annual Meeting and the 5th Congress of the European Academy of Neurology (EAN)
  13. Alnylam Completes Rolling NDA Submission to FDA for Givosiran
  14. Alnylam Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration (FDA) for Givosiran for the Treatment of Acute Hepatic Porphyria
  15. Alnylam Initiates Phase I Study on Hypertension Candidate
  16. Why Is Alnylam (ALNY) Down 16.8% Since Last Earnings Report?
  17. Alnylam Doses First Patient in Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension